Literature DB >> 19642528

[ISKRA guidelines on antimicrobial treatment and prophylaxis of urinary tract infections--Croatian national guidelines].

Visnja Skerk1, Arjana Tambić Andrasević, Sasa Andrasević, Edita Susić, Ana Mlinarić Dzepina, Vesna Madarić, Slobodan Milutinović, Ivan Krhen, Ljiljana Perić, Jugoslav Bagatin, Mario Corić, Daniel Ferlin, Irina Cazin, Gordana Tomac.   

Abstract

These guidelines refer to diagnosis, antimicrobial treatment and prophylaxis of urinary tract infections in adults and children older than 12 years of age and cover lower urinary tract in females, uncomplicated pyelonephritis, complicated UTI with or without pyelonephritis, asymptomatic bacteriuria and recurrent UTI. These guidelines do not cover sexually transmitted diseases. The guidelines are primarily intended for use by general practitioners and specialists working in primary health care and hospitals. The members of the Working Group for the development of guidelines on antimicrobial treatment and prophylaxis of urinary tract infections were appointed by the Croatian Ministry of Health and Social Welfare. The project was financially supported by the Dutch government and professional assistance was provided by international consultants. The evidence for this guidelines is based on a systematic review of the literature, local antibiotic resistance data, the existing clinical protocols on the treatment and prophylaxis of UTIs, as well as suggestions and comments made by colleagues physicians during more than 50 continuous medical education courses held in the last three years on antimicrobial treatment and prophylaxis of UTIs. Draft version of the guidelines was available for comments on the web site http://iskra.bfm.hr and during the two-month piloting period the guidelines were widely presented to general practitioners, specialists working in primary care and hospitals--urologists, gynecologists, infectious disease specialists, nephrologists. The final version of the guidelines was approved by the Intersectoral Coordination Mechanism for the Control of Antimicrobial Resistance (ISKRA) Board.

Entities:  

Mesh:

Year:  2009        PMID: 19642528

Source DB:  PubMed          Journal:  Lijec Vjesn        ISSN: 0024-3477


  6 in total

1.  Ceftriaxone treatment of complicated urinary tract infections as a risk factor for enterococcal re-infection and prolonged hospitalization: A 6-year retrospective study.

Authors:  Kristian Karlović; Jadranka Nikolić; Jurica Arapović
Journal:  Bosn J Basic Med Sci       Date:  2018-11-07       Impact factor: 3.363

Review 2.  Mechanisms of Resistance in Gram-Negative Urinary Pathogens: From Country-Specific Molecular Insights to Global Clinical Relevance.

Authors:  Branka Bedenić; Tomislav Meštrović
Journal:  Diagnostics (Basel)       Date:  2021-04-28

3.  Modeling of Urinary Microbiota Associated With Cystitis.

Authors:  Marina Ceprnja; Damir Oros; Ena Melvan; Ema Svetlicic; Jasenka Skrlin; Karmela Barisic; Lucija Starcevic; Jurica Zucko; Antonio Starcevic
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

4.  Pediatric tertiary emergency care departments in Zagreb, Rijeka, and Split before and during the coronavirus disease 2019 pandemic: a Croatian national multicenter study.

Authors:  Ante Šokota; Laura Prtorić; Iva Hojsak; Ivana Trivić; Filip Jurić; Kristina Lah Tomulić; Jelena Roganović; Harry Nikolić; Ana Bosak Veršić; Joško Markić; Marijan Batinić; Goran Tešović
Journal:  Croat Med J       Date:  2021-12-31       Impact factor: 1.351

5.  Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe.

Authors:  Josephine McQuiston Haslund; Marianne Rosborg Dinesen; Anni Brit Sternhagen Nielsen; Carl Llor; Lars Bjerrum
Journal:  Scand J Prim Health Care       Date:  2013-10-08       Impact factor: 2.581

6.  Outpatient Antibiotic Consumption for Urinary Infections in Croatia 2005 - 2014: What can be Learned from Utilization Trends.

Authors:  Željko Vojvodić; Danijela Daus Šebeđak
Journal:  Zdr Varst       Date:  2018-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.